Milestone ® Pharmaceuticals Inc. (Nasdaq: MIST) today announced submission of its response to the U.S. Food and Drug Administration (FDA)’s Complete Response Letter (CRL) regarding its New Drug ...

As previously reported, on February 28, 2025, Alzamend entered into a Securities Purchase & Exchange Agreement (the “ Agreement ”) with a sophisticated investor (the “ Investor ”), pursuant to which ...

Extendicare Inc. (“Extendicare” or the “Company”) (TSX: EXE) announced that it has declared a cash dividend of C$0.042 per common share of the Company for the month of June 2025, which is payable on ...

RESEARCH TRIANGLE PARK, N.C., June 16, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data on the long-term efficacy and safety of ORLADEYO ® (berotralstat) ...

GLP-1/GIP receptor co-agonist designed to be highly potent and for once-monthly administration based on MBX’s novel PEP™ platform technology . Phase 1 trial of MBX 4291 is exp ...

“Onco360 is grateful for the opportunity to partner with the team at Nuvation Bio and become a specialty pharmacy provider for IBTROZI,” said Benito Fernandez, Chief Commercial Officer at Onco360. “We ...

The partnership also includes a license for NextCure to access Simcere Zaiming’s proprietary linker and TOPOi payload for a preclinical-stage novel target ADC developed by NextCure. Simcere Zaiming ...

AD04 is Adial’s lead investigational drug, a serotonin-3 receptor antagonist, being developed for the treatment of Alcohol Use Disorder (AUD) in individuals with heavy drinking and select genotypes.

WEST PALM BEACH, FLORIDA, June 16, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (NYSE American: FOXO) (“ FOXO ” or the “ Company ”) today announced that it formed a new, wholly-owned subsidiary ...

Aurora Spine is excited to announce the upcoming Q4 2025 launch of DEXA-L™, a standalone Anterior Lumbar Interbody Fusion (ALIF) system built on the same award-winning DEXA platform. Like DEXA-C™, the ...

Istaroxime has completed four positive Phase 2 studies, including two in early cardiogenic shock (called SCAI Stage B). Market research conducted by the Company with U.S. based clinical cardiologists ...

Strengthens Supernus’ leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE ® (zuranolone), and a novel CNS discovery platform. Expected to be significantly ...